Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 5/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 3/20 | 0.35 |
| ▸ | USP28 | Q96RU2 | 6/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328642 | 0.84 | HTT (0.39) | HTTACACBGHSRL3MBTL1XIAP | |
| SCHEMBL20883667 | 0.84 | ALDH1A1 (0.45) | HTTACACBUSP28USP25XIAP | |
| SCHEMBL23328643 | 0.83 | HTT (0.47) | HTTACACBGHSRL3MBTL1XIAP | |
| SCHEMBL23328645 | 0.82 | GHSR (0.43) | ACACBGHSR | |
| SCHEMBL276903 | 0.81 | KDM4E (0.52) | HTTACACBPDE3BPDE3A | |
| SCHEMBL14924082 | 0.81 | KDM4E (0.52) | HTTACACBPDE3BPDE3A | |
| SCHEMBL30435989 | 0.79 | ALDH1A1 (0.49) | HTTPDE3BPDE3AGHSRL3MBTL1 | |
| SCHEMBL3567265 | 0.79 | ALDH1A1 (0.49) | HTTPDE3BPDE3AGHSRL3MBTL1 | |
| SCHEMBL15030365 | 0.77 | GHSR (0.41) | HTTGHSR | |
| SCHEMBL13239751 | 0.75 | L3MBTL1 (0.45) | HTTGHSRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | HTT 3713/4885ACACB 1389/4885PDE3B 3270/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | HTT 3679/4885ACACB 1169/4885PDE3B 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.